Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a phone app replace the gym for seniors with muscle loss?

NCT ID NCT07319377

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 2 times

Summary

This study tests a digital therapeutic device (exoDTx) – a mobile app that guides personalized resistance exercises at home – to see if it can improve muscle strength in people with sarcopenia (age-related muscle loss). 130 participants will either use the app for 12 weeks or receive standard educational materials. The main goal is to measure changes in knee extension strength.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
digital therapeutic device (exoDTx) – a mobile app guiding personalized resistance exercises at home
What this could lead to
If it works, this could offer a convenient, non-drug way to improve muscle strength in older adults with sarcopenia.
What could go wrong
This is a relatively small trial (130 people) and the device is still being tested. Results may not apply to everyone, and the app may not be as effective as supervised exercise.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 130 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Individuals diagnosed with sarcopenia according to both the European Working Group on Sarcopenia in Older People (EWGSOP) criteria and the Asian Working Group for Sarcopenia 2019 (AWGS 2019) criteria * Individuals with reduced muscle strength, defined as at least one of the following: * Handgrip strength \< 28 kg for men or \< 18 kg for women * Five-times Sit-to-Stand Test time \> 12 seconds without arm support * Individuals with reduced muscle mass, defined as at least one of the following: * Skeletal Muscle Mass Index (SMI) \< 7.0 kg/m² for men or \< 5.4 kg/m² for women measured by DXA * Skeletal Muscle Mass Index (SMI) \< 7.0 kg/m² for men or \< 5.7 kg/m² for women measured by BIA * Individuals able to independently perform sit-to-stand movements * Individuals with sufficient physical and cognitive capacity to participate in the exercise program * Individuals able and willing to provide written informed consent * Individuals able to operate a mobile phone independently or with assistance from a caregiver Exclusion Criteria * Individuals with cognitive impairment, defined as a Mini-Mental State Examination (MMSE) score \< 20, or those unable to participate due to cognitive decline * Individuals with an implanted cardiac pacemaker or other implanted electronic medical device * Individuals with uncontrolled cardiovascular disease despite appropriate medical management * Individuals who have undergone lower-limb surgery within the past 6 months and are unable to ambulate independently * Individuals with moderate-to-severe musculoskeletal pain or functional limitations that interfere with objective functional assessments * Individuals with severe obesity, defined as a body mass index (BMI) \> 50 kg/m² * Individuals currently receiving active cancer treatment or experiencing severe systemic frailty * Individuals with hemiplegia that prevents participation in the prescribed exercise program * Individuals who are anticipated by the investigator to be unable to complete the study procedures or follow-up assessments * Individuals unable to understand or comply with study instructions provided in Korean * Individuals considered unsuitable for study participation at the discretion of the investigator for any other reason

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sarcopenia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Bucheon St. Mary's Hospital

    Bucheon-si, South Korea

  • St.Vincent's hospital

    Suwon, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.